Bone marrow transplantation: a new strategy for intractable diseases

Area of Science:

• Immunology
• Regenerative Medicine
• Transplantation Biology

Background:

• Bone marrow transplantation (BMT) is a potent therapy for hematologic and autoimmune diseases.
• Allogeneic BMT has shown success in treating various autoimmune conditions in animal models and humans.
• However, challenges remain, including graft recurrence and the need for potent conditioning regimens.

Purpose of the Study:

• To investigate a novel intra-bone marrow injection (IBMI) BMT strategy for treating autoimmune diseases.
• To evaluate the efficacy and safety of IBMI BMT in radioresistant autoimmune models, specifically MRL/lpr mice.
• To explore the role of donor stromal cells and optimize conditioning protocols.

Main Methods:

• Developed and tested an intra-bone marrow injection (IBMI) technique for allogeneic bone marrow cell transplantation.
• Utilized MRL/lpr mice, a model for autoimmune diseases, with modified irradiation protocols (fractionated irradiation, reduced doses).
• Employed a novel 'perfusion method' for collecting bone marrow cells from cynomolgus monkeys, minimizing T-cell contamination.

Main Results:

• IBMI BMT completely prevented autoimmune disease recurrence in MRL/lpr mice, even with reduced radiation doses (5 Gy x 2).
• This strategy led to long-term survival (>1 year) and complete restoration of immunological functions.
• The IBMI approach demonstrated no graft-versus-host disease, no graft failure, rapid hematopoietic recovery, and restored T-cell function across MHC barriers.

Conclusions:

• Intra-bone marrow injection bone marrow transplantation is a superior strategy for allogeneic BMT, offering improved outcomes and reduced toxicity.
• This method holds significant potential for treating intractable autoimmune diseases without immunosuppressants.
• The perfusion method for cell collection and IBMI BMT represent a powerful new approach for transplantation and regenerative therapy.